Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
27 10 2023
27 10 2023
Historique:
medline:
27
10
2023
pubmed:
25
10
2023
entrez:
25
10
2023
Statut:
ppublish
Résumé
Recent studies have pointed to PARP1 trapping as a key determinant of the anticancer effects of PARP1 inhibitors (PARPi). We identified RNF114, as a PARylation-dependent, E3 ubiquitin ligase involved in DNA damage response. Upon sensing genotoxicity, RNF114 was recruited, in a PAR-dependent manner, to DNA lesions, where it targeted PARP1 for degradation. The blockade of this pathway interfered with the removal of PARP1 from DNA lesions, leading to profound PARP1 trapping. We showed that a natural product, nimbolide, inhibited the E3 ligase activity of RNF114 and thus caused PARP1 trapping. However, unlike conventional PARPi, nimbolide treatment induced the trapping of both PARP1 and PARylation-dependent DNA repair factors. Nimbolide showed synthetic lethality with
Identifiants
pubmed: 37878693
doi: 10.1126/sciadv.adg7752
pmc: PMC10599614
doi:
Substances chimiques
nimbolide
25990-37-8
Poly(ADP-ribose) Polymerase Inhibitors
0
DNA
9007-49-2
PARP1 protein, human
EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1
EC 2.4.2.30
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
eadg7752Subventions
Organisme : NINDS NIH HHS
ID : R01 NS122533
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA261018
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM134883
Pays : United States
Références
Am Soc Clin Oncol Educ Book. 2019 Jan;39:79-86
pubmed: 31099688
Hum Mol Genet. 2011 Aug 15;20(16):3129-37
pubmed: 21571784
J Proteome Res. 2016 Feb 5;15(2):477-86
pubmed: 26736068
Cell Death Dis. 2014 Aug 28;5:e1399
pubmed: 25165885
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Nat Commun. 2018 May 10;9(1):1849
pubmed: 29748565
Ann Oncol. 2019 Apr 1;30(4):558-566
pubmed: 30689707
Nat Commun. 2019 Jul 19;10(1):3201
pubmed: 31324758
ACS Chem Biol. 2016 Nov 18;11(11):3179-3190
pubmed: 27689388
Biochem J. 1999 Sep 1;342 ( Pt 2):249-68
pubmed: 10455009
Nat Rev Cancer. 2010 Apr;10(4):293-301
pubmed: 20200537
Nat Cell Biol. 2022 Jan;24(1):62-73
pubmed: 35013556
Nat Protoc. 2006;1(6):2820-7
pubmed: 17406540
Nat Rev Mol Cell Biol. 2012 Jun 20;13(7):411-24
pubmed: 22713970
Annu Rev Biochem. 2015;84:227-63
pubmed: 25747399
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
Clin Cancer Res. 2013 Sep 15;19(18):5003-15
pubmed: 23881923
J Clin Oncol. 2019 Nov 10;37(32):2968-2973
pubmed: 31173551
Mol Cancer Ther. 2014 Feb;13(2):433-43
pubmed: 24356813
Cell Death Differ. 2013 Aug;20(8):1055-67
pubmed: 23645206
Cell Chem Biol. 2021 Apr 15;28(4):456-462
pubmed: 33657415
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Toxicol In Vitro. 2014 Aug;28(5):1026-35
pubmed: 24759803
N Engl J Med. 2009 Jul 9;361(2):123-34
pubmed: 19553641
Nat Cell Biol. 2001 Jan;3(1):93-6
pubmed: 11146632
Cell Rep. 2020 Aug 4;32(5):107985
pubmed: 32755579
J Biol Chem. 2001 Nov 16;276(46):42938-44
pubmed: 11557750
Science. 2020 Apr 3;368(6486):
pubmed: 32241924
Molecules. 2021 Jan 06;26(2):
pubmed: 33419112
Ann Oncol. 2016 Jun;27(6):1013-1019
pubmed: 26961146
Biochem Biophys Res Commun. 1963 Apr 2;11:39-43
pubmed: 14019961
DNA Repair (Amst). 2017 Apr;52:81-91
pubmed: 28254358
Ann Oncol. 2019 Sep 1;30(9):1437-1447
pubmed: 31218365
Cell Biochem Funct. 2014 Apr;32(3):217-28
pubmed: 23963693
Invest New Drugs. 2014 Apr;32(2):213-26
pubmed: 24114124
Nat Commun. 2022 May 31;13(1):3022
pubmed: 35641483
Genes Dev. 2017 Feb 1;31(3):318-332
pubmed: 28242626
Evid Based Complement Alternat Med. 2012;2012:303019
pubmed: 22461839
Mol Carcinog. 2012 Jun;51(6):475-90
pubmed: 21678498
Nat Genet. 2010 Nov;42(11):1000-4
pubmed: 20953189
Nat Commun. 2019 Mar 12;10(1):1182
pubmed: 30862789
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Nat Chem Biol. 2019 Jul;15(7):747-755
pubmed: 31209351
Nat Chem Biol. 2019 Dec;15(12):1223-1231
pubmed: 31659317
Cancer Discov. 2020 Jan;10(1):26-39
pubmed: 31852718
Oncotarget. 2016 Jul 12;7(28):44790-44802
pubmed: 27027349
Nature. 2017 Jan 5;541(7635):87-91
pubmed: 28002403
Life Sci. 1996;58(13):1075-81
pubmed: 8622560
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Mol Cell. 2014 Apr 24;54(2):289-96
pubmed: 24766893
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
Nucleic Acids Res. 2017 Aug 21;45(14):8129-8141
pubmed: 28854736
Mol Cell. 2021 Jul 15;81(14):3018-3030.e5
pubmed: 34102106
Nature. 1992 Mar 26;356(6367):356-8
pubmed: 1549180
Ann Oncol. 2020 Nov;31(11):1526-1535
pubmed: 32828825
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15532-7
pubmed: 25313037
Cell Death Differ. 2019 Mar;26(3):516-530
pubmed: 29899380
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
DNA Repair (Amst). 2018 Jan;61:25-36
pubmed: 29179156
Nat Immunol. 2016 Sep 20;17(10):1142-9
pubmed: 27648547
Biochemistry. 2018 Jan 30;57(4):429-440
pubmed: 29327913
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Mol Cell Biol. 1998 Jun;18(6):3563-71
pubmed: 9584196
Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1637-1642
pubmed: 28137885
Trends Cell Biol. 2019 Oct;29(10):820-834
pubmed: 31421928
Breast Cancer Res Treat. 2012 Jul;134(2):511-7
pubmed: 22562176
Mol Cancer Ther. 2011 Apr;10(4):591-602
pubmed: 21321066
Oncotarget. 2015 Dec 29;6(42):44289-305
pubmed: 26517239
Elife. 2020 Aug 26;9:
pubmed: 32844745
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
J Am Soc Mass Spectrom. 2017 Oct;28(10):2078-2089
pubmed: 28752479
Sci Rep. 2018 Apr 18;8(1):6161
pubmed: 29670134